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ABSTRACT
Objective: Holoprosencephaly (HPE) is heterogeneous in pathogenesis, integrating genetic 
susceptibility with the influence of environmental factors. Submicroscopic aberrations may 
contribute to the etiology of HPE. Our aim was to report the molecular analysis of 4 fetuses 
with HPE and normal metaphase karyotype. Method: A whole genome BAC-array based 
Comparative Genomic Hybridization (array CGH) was carried out in fetal blood samples. All 
potential cytogenetic alterations detected on the arrays were matched against the known copy 
number variations databases. Results: The array CGH analysis showed copy number gains and 
losses in all cases. We found a recurrent deletion in 15q14 (clone RP11-23J11) and in 15q22 
(clone RP11-537k8) in 2 out 4 cases analyzed. We also observed submicroscopic gain in 6p21 in 3 
out of 4 fetuses in nearby clones. All these regions were tested in known databases and no copy 
number variations have been described for them. Conclusion: This is the first report of molecular 
characterization through a whole genome microarray CGH of fetuses with HPE. Our results may 
contribute to verify the effectiveness and applicability of the molecular technique of array CGH 
for prenatal diagnosis purposes, and contributing to the knowledge of the submicroscopic 
genomic instability characterization of HPE fetuses.
Key words: holoprosencephaly, comparative genomic hybridization, prenatal diagnosis, genetic 
testing, genomic instability.
Instabilidades genômicas detectadas através de array CGH em fetos com holopro sencefalia
RESUMO
Objetivo: Holoprosencefalia (HPE) é uma malformação heterogênea na patogênese, 
integrando a suscetibilidade genética com a influência de fatores ambientais. Aberrações 
submicroscópicas podem contribuir para a etiologia da HPE. Nosso objetivo foi relatar a 
análise molecular de 4 fetos com HPE e cariótipo normal. Método: Foi realizado um estudo 
descritivo prospectivo dos achados da técnica de hibridação genômica comparativa baseada 
em microarranjos utilizando BAC clones de ampla cobertura genômica (BAC-array CGH) 
em amostras sanguíneas de fetos portadores de holoprosencefalia e com cromossomos 
numericamente normais ao bandamento G. Todas as potenciais alterações citogenéticas 
detectadas foram comparadas com bancos de dados com variações do número de cópias 
conhecidas. Resultados: A análise de array CGH evidenciou ganhos e perdas do número de 
cópias em todos os 4 casos. Foram encontradas deleções recorrentes em 15q14 (clone RP11-
23J11) e em 15q22 (clone RP11-537k8) em 2 dos 4 casos analisados. Observou-se em 3 fetos 
ganho genômico na região 6p21 em clones próximos. Todas estas regiões não apresentaram 
variações do número de cópias descritas em bancos de dados conhecidos. Conclusão: Este 
é o primeiro relato de caracterização molecular através de um microarray CGH de fetos com 
HPE. Nossos resultados podem contribuir para verificar a eficácia e aplicabilidade da técnica 
molecular de array CGH para fins de diagnóstico pré-natal, contribuindo para o conhecimento 
da caracterização de instabilidades genômicas submicroscópicas de fetos com HPE. 
Palavras-chave: holoprosencefalia, hibridização genômica comparativa, diagnóstico pré-natal, 
análise genética, instabilidade genômica.
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Holoprosencephaly (HPE) OMIM 2361000, is the 
most common developmental defect of midline cleavage 
in human embryonic forebrain, with a variable pheno-
typic expression. Its estimated prevalence is of 1:16,000 
live-births1 and 1:250 conceptuses2, but it should be high-
er considering the current advances in neuroimaging that 
allow the diagnosis of less severe forms of this malfor-
mation. The association of holoprosencephaly with oth-
er fetal structural and chromosomal abnormalities justi-
fies a detailed investigation of the fetal morphology and 
karyotype.
Our current understanding of the pathogenesis of 
HPE attempts to integrate genetic susceptibility with the 
epigenetic influence of environmental factors. Identifiable 
genetic causes in humans account for about 15-20% of all 
cases3. The most common chromosomal abnormality as-
sociated to holoprosencephaly is the trisomy 13. To date, 
known human mutations in at least 12 different genetic 
loci have been associated with HPE4, but a very small per-
centage of all cases has a molecularly defined HPE. There-
fore, submicroscopic aberrations may contribute to the 
etiology of HPE.
The aim of this study was to report the molecular 
findings through a whole genome array comparative ge-
nomic hybridization (array CGH) of 4 fetuses with pre-
natal ultra-sound diagnosis of HPE in an attempt to im-
prove the knowledge of the submicroscopic abnormali-
ties presented in these malformed fetuses.
METHOD
Patients and samples
For this study, fetuses with holoprosencephaly as an 
isolated brain malformation, no recognized genetic syn-
drome, and normal metaphase karyotype delivered be-
tween January 2008 and July 2009 were prospectively in-
cluded. This study was carried out after the protocol ap-
proval by the institution’s ethical committee.
The fetal and parental karyotype analysis was per-
formed using G-banded metaphase chromosomes at ap-
proximately the 500 band level. All the parents gave in-
formed consent. The presence and morphologic classifi-
cation of HPE was confirmed by postnatal MRI (magnetic 
resonance imaging) or autopsy reports. Maternal diabe-
tes mellitus, drug ingestion, exposure to alcohol and in-
fections were excluded. 
Fetal blood samples were collected by cordocentesis 
at different week’s gestation for karyotype, according to 
the guidelines of the Fetal Medicine Unit of the Women’s 
Hospital of the State University of Campinas (Unicamp).
Molecular study
Genomic DNA was extracted and purified from fetal 
blood by means of the Wizard® Genomic DNA Purifica-
tion Kit (Promega Corp., Madison, WI, USA), according 
to manufacturer’s protocol for whole blood. 
Array Comparative Genomic Hybridization was car-
ried out using the Constitutional Chip® 4.0 (PerkinElmer 
Inc., Turku, Finland), comprised of approximately 5000 
BAC (Bacterial Artificial Chromosome) clones, covering 
the whole human genome with an average resolution of 
<650 kb and spotted in duplicate. 
For each experiment, a sex-mismatched normal ref-
erence DNA (Promega Corp., Madison, WI, USA) was 
used. The DNA concentrations used were 40 ng/µl. All 
experiments included dye reversal and two array hybrid-
izations to obtain an accurate ratio. After post-hybrid-
ization washes, slides were scanned, and captured imag-
es were analyzed by either the GenePix® Pro 6.0 (Molec-
ular Devices Corp.) or the ScanArray Express® (Microar-
ray Analysis System 4.0.0.4) software.
After quantification, the cyanine 5 and cyanine 3 av-
erage ratio fluorescence intensities for each BAC clone on 
each of the duplicate arrays (gpr files) were uploaded into 
the web-based SpectralWare® v2.3.3 software (PerkinEl-
mer Inc.), normalized with linear regression algorithms 
(on a log2 scale) and plotted according to the BAC chro-
mosomal location. The raw data from dye-reversed pairs 
were combined, and threshold values were ascertained 
to make inferences according to a clone-by-clone clas-
sification procedure to determine the gain, loss and no 
change status of each clone for each subject, relative to 
the diploid reference DNA. The threshold values were 
determined by the software using the “Iterative 2.5X Sig-
mas” algorithm. Subsequent normalization of the data 
with “Block Lowess” method was performed for verifi-
cation of copy number changes. The P values for each 
probe were also calculated, furnishing additional objec-
tive statistical criteria to determine whether deviation of 
each probe from zero is a significant change5. The quality 
criteria adopted included standard deviation of the inten-
sity ratios among the duplicates less than 10% and more 
than 97.5% of spots with adequate intensity ratio values 
for analysis6. For each analysis, all quality control metrics 
were noted to be optimal. Clone-by-clone changes were 
reviewed and only those aberrations detected in both hy-
bridizations were studied further.
All potential cytogenetic alterations detected on the 
arrays were matched against the known online databases 
to determine whether they encompassed described copy 
number variations (CNV) regions.
RESULTS
Four unrelated fetuses were included in this study. 
There was no family history of congenital malformations 
or genetic disorders. Both women and their husbands 
were healthy, no consanguineous and presented normal 
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chromosomes at G-band analysis of peripheral blood. The 
maternal age ranged from 14 to 36 years old, with a par-
ity varying from zero to two. One woman had previous 
spontaneous abortions, with no investigation for cytoge-
netics aberrations. The fetuses’ hearts were morpholog-
ically normal at the fetal echocardiography. All the four 
babies were born alive with adequate weight for the ges-
tational age and two of them, the semi-lobar and the alo-
bar cases, died in the same day. An autopsy confirmed 
the prenatal findings and classification of HPE in all cas-
es. The array CGH analysis showed copy number gains 
and losses in all cases.
Clinical aspects, the gestation outcome and the total 
number of clones with genomic instability observed in 
each case are summarized in Table 1.
We identified recurrent deletion in 15q14 and in 
15q22 in 2 out 4 cases analyzed. Based on the physi-
cal mapping positions as obtained from the March 2006 
and February 2009 Assembly of the UCSC Genome 
Browser (http://genome.ucsc.edu/), the size of the delet-
ed regions were determined to be 40,492 bp (37,806,124-
37,846,615) and 174,345 bp (62,082,000-62,256,344), re-
spectively. We also observed a recurrent copy number 
gain in 6p21 region in 3 out of 4 evaluated fetuses in-
volving different but close clones (Figure). The complete 
list of abnormal clones found in the four fetuses is listed 
in Table 2. Details about the recurrent abnormal clones 
are listed in Table 3.
All the identified common regions were tested in 
known databases and four copy number variations (CNV) 
were found and excluded. They were gain at 1p36, 2q37.3 
and 9q34, and loss at 5q13.
Table 1. Clinical aspects, gestation outcome and the total number of clones with genomic instability in 4 fetuses with holoprosencephaly.







#1 36 G3 P2 A0 Lobar 33 46,XX 20 36 Alive
#2 14 G1 P0 A0 Lobar 31 46,XY 17 39 Alive
#3 28 G2 P1 A0 Semi lobar 31 46,XY 22 41 Died in 
1 hour
#4 28 G1 P0 A0 Alobar 27 46,XY 05 35 Died in 
10 min.
GA: gestational age (weeks); *Maternal age (completed years); **G: gravidity, P: parity, A: number of abortions; ***Total number of abnormal clones.
Table 2. Abnormal clones detected in 4 fetuses with holoprosencephaly using whole genome array CGH.
#1 #2 #3 #4
G L G L G L G L
RP1-283E3 RP11-328L16 RP4-628J24 RP11-23J11 RP11-625N16 RP11-91G12 RP11-353K11
RP1-160H23 RP3-375M21 RP1-77N19 RP11-537K8 RP11-118M12 RP11-352A18 RP5-1011O17
RP11-602P21 RP11-173D3 RP5-856G1 RP11-300G13 RP3-462C17 RP11-551B22 RP11-15M20
RP11-48C7 RP1-86C11 RP11-483F11 RP11-3G21 RP1-103M22
RP1-44H16 RP3-428L16 GS-261-B16 RP11-107O19 RP11-80F22
GS-908-H22 RP3-366N23 RP11-416K5 RP11-23J11











L: Loss; G: Gain.
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DISCUSSION
HPE seems to be a multiple hit pathology, requiring 
two or more events involving several genes and/or envi-
ronmental factors7. The pathology of HPE can be caused 
by environmental (drugs, infections) and metabolic (dia-
betes mellitus, alcohol, smoking) factors. Among genet-
ic causes, it can be part of defined malformations syn-
dromes with normal karyotype, chromosomal abnormal-
ities as trisomy 13, trisomy 18 and triploidy, or it can be 
due to known sequence mutations on described chro-
mosome regions.
The currently identified HPE genes only account for 
a small portion of all sporadic HPE cases (15-20%)3, and 
mutations in the currently recognized HPE genes explain 
only a very small proportion of all sporadic HPE cases8. 
In a cohort of 424 unrelated postnatal cases with severe 
central nervous system findings, normal karyotype and 
negative for the for four main HPE genes, micro deletions 
were found in 4.7% and no micro deletions were found 
in 85 individuals with HPE microsigns9. The same group 
of researchers found a percentage of 8.5% of microdele-
tions in the prenatal period in 97 fetuses10. The remaining 
cases are assumed to be a non-known etiology manifes-
tation: neither environmental, nor syndromic, nor chro-
mosomal4. The difficulties in identifying these genes may 
relate to the multigenic nature of HPE. Loss of function 
in a single HPE gene may not lead to the disease. In hu-
man, there will be other modifier genes acting in addi-
tion11. A recent study involving twenty members of an af-
fected family showed the importance of perseverance de-
spite initially negative tests, including applying new tech-
nology and testing newly discovered genes and highlight-
ed the fact that genetic disorders may manifest in ways 
not exactly as traditionally described12.
Therefore, we hypothesized that there are still uniden-
tified genes causing underlying submicroscopic aberra-
tions that could contribute to the etiology of HPE. In a 
first attempt to identify novel candidate regions involved 
in the pathology of this heterogeneous disease, and to 
evaluate the feasibility of BAC arrays in the analysis of 
prenatal samples, we used an array CGH pangenomic ap-
proach to report the molecular characterization of group 
of 4 fetuses with normal karyotype and diagnosis of HPE 
visible by ultra-sound prenatal care.
Table 3. Recurrent abnormal clones in 4 fetuses with holoprosencephaly.
Clone Chromosome region Size (bp) Affected cases
RP11-23J11 15q14 40,492 #2, #3
RP11-537k8 15q22 174,345 #2, #3
RP3-462C17 6p21.1 118,106 #3
RP11-602P21 6p21.2 224,030 #1
RP1-86C11 6p21.3 89,016 #2
bp: base pairs.
Figure. Spectral view of chromosome 6 showing recurrent gain at 6p21.
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The array CGH analysis showed copy number gains 
and losses in all cases. Interestingly, the alobar case, the 
more severely affected fetus, presented the smallest num-
ber of genomic abnormalities. Indeed, our results did not 
allow an inkling of correlation between the number and 
size of these imbalances and the severity of the phenotype.
The current described genes and candidate genes for 
HPE, with its respective chromosome regions are pre-
sented in Table 44. It was not a goal of this study to search 
for mutations in the four main HPE genes (SHH, ZIC2, 
SIX3, TGIF), but we could observe that there were no ab-
normal clones in their known loci.
A Medline search using the keywords 15q14 and ho-
loprosencephaly could not find any citation. The same 
occurred using the association between 15q22 or 6p21 
and holoprosencephaly. One patient was related with a 
de novo reciprocal translocation affecting the breakpoints 
6p21.1 and 7q36, presenting premaxillary agenesis (part 
of the HPE spectrum) as well as skeletal abnormalities 
and impacted teeth reminiscent of cleidocranial dyspla-
sia (CCD). But, in this patient, the HPE phenotype could 
be explained by the 7q36 breakpoint that maps to the 
sonic hedgehog gene (SHH), the HPE3 described locus13. 
As the mutations in genes mapping the 6p21 region can 
cause CCD, the breakpoint in this region in this case ap-
pears to explain the CCD phenotype14.
A possible association between the 15q22 region and 
holoprosencephaly could be postulated considering that, 
in some instances, the agenesis of corpus callosum can 
be part of the holoprosencephaly spectrum3. Of the clin-
ical manifestations reported cases of individuals with 
deletions encompassing 15q15-q22 region, one patient 
showed partial agenesis of corpus callosum15 and other 
showed hypoplastic corpus callosum16.
The inheritance background of our findings is un-
known as blood samples from the parents were not avail-
able for array CGH analysis to determine if the copy num-
ber gains were inherited or de novo.
The greatest care must be taken for molecular prena-
tal diagnosis in HPE. Even if a mutation has been identi-
fied and seems to be transmitted with clinical manifesta-
tions in the family, another event, like a mutation in an-
other gene (not yet identified) or an environmental fac-
tor, may be necessary to generate the holoprosencepha-
ly phenotype7. In this case, molecular biology performed 
prenatally provides only an additional criterion with re-
gard to prenatal ultrasound or MRI, which still takes pre-
cedence over molecular analysis.
Microarray-based CGH is a powerful method to de-
tect and analyze genomic imbalances that are well below 
the level of detection on high resolution banded karyo-
type analysis providing a better opportunity for genotype/
phenotype correlations in other similarly affected indi-
viduals. Array CGH is relatively widely used in genetic 
testing of children. Recently, a case with the middle in-
terhemispheric variant, a milder variant of HPE, was de-
scribed carrying a deletion of ~10.4 Mb at 6q22.31-q23.2, 
suggesting a novel candidate gene of HPE17. But its true 
potential is still under-explored in prenatal diagnosis.
Some advantages of this molecular method is that 
it does not involve cell culture, does not require prior 
knowledge of the genomic region involved and the ability 
to study cases where only DNA is available and no chro-
mosomes can be obtained. The method was reproduc-
ible in a clinical standpoint, with reliable results within 48 
hours. Thus, we demonstrate that the technique of array 
CGH can become an excellent tool for prenatal diagnosis. 
But, it is important to emphasize that array CGH may not 
replace conventional G-banded karyotype analysis, but it 
can complement and expand current methods for a pre-
cise prenatal diagnosis and syndromes’ characterization. 
One advantage of G banding analysis is that it allows the 
detection of somatic chromosomal mosaicism, which has 
been described in some patients with PHE.
Based on our results, array CGH results are promising 
in prenatal genetic testing and a study for submicroscopic 
deletions in fetuses with non-syndromic HPE should be 
Table 4. Known genes and candidate genes for HPE.
LOCI and known HPE genes Candidate genes
236100 HPE1 21q22.3 Investigated or under 
investigation
157170 HPE2 2p21 SIX3 600909 LSS 21q22,3 HPE1 
142945 HPE3 7q36 SHH 605194 CFC1 2q21.1 
142946 HPE4 18p11.3 TGIF 181590 SIL 1p32 
609637 HPE5 13q32 ZIC2 605189 DKK1 10q11.2 
605934 HPE6 2q37.1-q37.3 Hypothetical 
601309 HPE7 9q22.3 PTCH 602103 TMEM1 21q22.3 
609408 HPE8 14q prox 600288 FOXA2 20p11 
– HPE9 20p13 607502 DISP1 1q42 
– HPE10 1q42-qter 609486 EAPP 14q13 HPE8 
– HPE11 5pter 609863 TECT1 12q24.1 
– HPE12 6q26-qter 603475 CHRD 3q27 
600725 gene SHH 7q36 602991 NOG 17q22 
602630 gene TGIF 18p11.3 600073 LPR2 2q24-q31
603073 gene ZIC2 13q32 601500 SMO 7q32.2 
603714 gene SIX3 2p21 606178 HHIP 4q31.22 
187395 gene TDGF1 3p23-p21 112262 BMP4 14q22.2 
601309 gene PTCH 9q22 601265 NODAL 10q22.1 
603621 gene FOXH1 8q24.3 601366 SMAD2/4 18q21 
165230 gene GLI2 2q14 608707 CDO 11q23-q24 
605049 TWSG1 18p11.3 
Dubourg et al.4, 2007.
Arq Neuropsiquiatr 2011;69(1)
8
Array CGH in fetuses with holoprosencephaly
Machado et al.
considered as part of the routine laboratory evaluation, in 
addition to high resolution chromosomal and mutation 
analysis. Positive results in any of these studies will help 
to better understand the etiology of HPE and aid the es-
tablishment of the recurrence risk for family counseling. 
Moreover, additional research is needed to further estab-
lish the role of genes from related chromosome regions 
in brain development and to determine the prevalence of 
copy number gain in the 15q and 6p regions among HPE 
patients. Also, in accordance with others authors, epide-
miologic investigations should be conducted to check off 
environmental factors that could act in coordination with 
genetic events to give rise to holoprosencephaly.
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